300199 翰宇药业
已收盘 07-17 15:00:00
资讯
新帖
简况
翰宇药业（300199）披露2026年限制性股票激励计划内幕信息知情人买卖公司股票情况自查报告，7月13日股价下跌7.63%
证券之星 · 07-13
翰宇药业（300199）披露2026年限制性股票激励计划内幕信息知情人买卖公司股票情况自查报告，7月13日股价下跌7.63%
翰宇药业（300199）披露2026年半年度业绩预告，7月10日股价下跌1.32%
证券之星 · 07-10
翰宇药业（300199）披露2026年半年度业绩预告，7月10日股价下跌1.32%
翰宇药业最新公告：预计2026年半年度净利润同比增长54.67%-68.42%
证券之星 · 07-10
翰宇药业最新公告：预计2026年半年度净利润同比增长54.67%-68.42%
翰宇药业：预计上半年净利润同比增长54.67%-68.42%
格隆汇 · 07-10
翰宇药业：预计上半年净利润同比增长54.67%-68.42%
翰宇药业最新公告：全资子公司化学原料药利拉鲁肽获上市批准
证券之星 · 07-06
翰宇药业最新公告：全资子公司化学原料药利拉鲁肽获上市批准
翰宇药业（300199）披露司美格鲁肽注射液（减重）上市申请获受理公告，7月3日股价上涨8.14%
证券之星 · 07-03
翰宇药业（300199）披露司美格鲁肽注射液（减重）上市申请获受理公告，7月3日股价上涨8.14%
翰宇药业(300199.SZ)拟推2026年限制性股票激励计划
智通财经 · 07-02
翰宇药业(300199.SZ)拟推2026年限制性股票激励计划
翰宇药业利拉鲁肽注射液获国家药监局批准用于治疗成人2型糖尿病
美股速递 · 07-01
翰宇药业利拉鲁肽注射液获国家药监局批准用于治疗成人2型糖尿病
翰宇药业：利拉鲁肽注射液获批上市
格隆汇 · 07-01
翰宇药业：利拉鲁肽注射液获批上市
翰宇药业(300199.SZ)：替尔泊肽注射液降糖及减重2个ANDA获得美国FDA首仿受理
智通财经 · 06-30
翰宇药业(300199.SZ)：替尔泊肽注射液降糖及减重2个ANDA获得美国FDA首仿受理
翰宇药业宣布美国FDA认定替尔泊肽注射液申请基本完整并接受审评
美股速递 · 06-30
翰宇药业宣布美国FDA认定替尔泊肽注射液申请基本完整并接受审评
股市必读：翰宇药业（300199）6月26日董秘有最新回复
证券之星 · 06-29
股市必读：翰宇药业（300199）6月26日董秘有最新回复
翰宇药业：公司今年上半年签订的1.8亿元及3.27亿元人民币的GLP-1原料药订单均属于框架性约定
证券之星 · 06-26
翰宇药业：公司今年上半年签订的1.8亿元及3.27亿元人民币的GLP-1原料药订单均属于框架性约定
翰宇药业（300199）披露控股股东办理股票质押业务公告，6月23日股价下跌1.02%
证券之星 · 06-23
翰宇药业（300199）披露控股股东办理股票质押业务公告，6月23日股价下跌1.02%
翰宇药业(300199.SZ)子公司利那洛肽化学原料药获得上市申请批准
智通财经 · 06-22
翰宇药业(300199.SZ)子公司利那洛肽化学原料药获得上市申请批准
翰宇药业：流动性压力可控
证券之星 · 06-05
翰宇药业：流动性压力可控
翰宇药业：公司相关项目已取得阶段性进展
证券之星 · 06-05
翰宇药业：公司相关项目已取得阶段性进展
翰宇药业最新公告：卡贝缩宫素原料药获欧盟DCP核准
证券之星 · 06-01
翰宇药业最新公告：卡贝缩宫素原料药获欧盟DCP核准
翰宇药业（300199）披露2025年年度股东会决议公告，5月21日股价下跌3.19%
证券之星 · 05-21
翰宇药业（300199）披露2025年年度股东会决议公告，5月21日股价下跌3.19%
翰宇药业最新公告：签订多肽原料药销售合作框架协议拟定销售金额不低于3.27亿元
证券之星 · 05-19
翰宇药业最新公告：签订多肽原料药销售合作框架协议拟定销售金额不低于3.27亿元
暂无数据
公司概况
公司名称：
深圳翰宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-04-07
主营业务：
深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。
发行价格：
30.19
{"stockData":{"symbol":"300199","market":"SZ","secType":"STK","nameCN":"翰宇药业","latestPrice":21.44,"timestamp":1784271831000,"preClose":24.47,"halted":0,"volume":76335041,"delay":0,"changeRate":-0.1238,"floatShares":745000000,"shares":883000000,"eps":0.1071,"marketStatus":"已收盘","change":-3.03,"latestTime":"07-17 15:00:00","open":24.36,"high":24.5,"low":21.38,"amount":1718000000,"amplitude":0.1275,"askPrice":21.45,"askSize":619,"bidPrice":21.44,"bidSize":356,"shortable":0,"etf":0,"ttmEps":0.1071,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784511000000},"marketStatusCode":5,"adr":0,"adjPreClose":24.47,"symbolType":"stock","openAndCloseTimeList":[[1784251800000,1784259000000],[1784264400000,1784271600000]],"highLimit":26.92,"lowLimit":22.02,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":883241336,"isCdr":false,"pbRate":29.15,"roa":"--","peRate":200.186741,"roe":"18.86%","epsLYR":0.04,"committee":0.175303,"marketValue":18937000000,"turnoverRate":0.1024,"status":1,"floatMarketCap":15976000000},"requestUrl":"/m/hq/s/300199/tweets","defaultTab":"tweets","newsList":[{"id":"2651626117","title":"翰宇药业（300199）披露2026年限制性股票激励计划内幕信息知情人买卖公司股票情况自查报告，7月13日股价下跌7.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651626117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651626117?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:05","pubTimestamp":1783951524,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘，翰宇药业报收于23.5元，较前一交易日下跌7.63%，最新总市值为207.56亿元。该股当日开盘25.03元，最高25.44元，最低23.37元，成交额达14.32亿元，换手率为7.97%。近日，翰宇药业发布《关于2026年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告》。经向中国证券登记结算有限责任公司深圳分公司查询，所有内幕信息知情人在自查期间均不存在买卖公司股票的行为。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300039789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0070","BK0077","BK0028","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650135507","title":"翰宇药业（300199）披露2026年半年度业绩预告，7月10日股价下跌1.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650135507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650135507?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:11","pubTimestamp":1783692678,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，翰宇药业报收于25.44元，较前一交易日下跌1.32%，最新总市值为224.7亿元。近日，深圳翰宇药业股份有限公司发布2026年半年度业绩预告，预计2026年1月1日至6月30日营业收入为68,000.00万元至70,000.00万元，同比增长23.76%-27.40%；归属于上市公司股东的净利润为22,500.00万元至24,500.00万元，同比增长54.67%-68.42%；扣除非经常性损益后的净利润为21,700.00万元至23,700.00万元，同比增长75.88%-92.09%。该数据未经会计师事务所审计，最终数据以2026年半年度报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0077","300199","BK0028","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650818660","title":"翰宇药业最新公告：预计2026年半年度净利润同比增长54.67%-68.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650818660","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650818660?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:23","pubTimestamp":1783675392,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，预计2026年半年度归属于上市公司股东的净利润为2.25亿元-2.45亿元，同比增长54.67%-68.42%。业绩变动主要系原料药业务持续放量，带来营收、利润双增长，同时财务精细化管理水平提升，费用管控合理。注：公司Q2净利润预计0.97亿-1.17亿，Q1净利润1.28亿，据此计算，Q2净利润预计环比下降8%-23%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000031120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650118545","title":"翰宇药业：预计上半年净利润同比增长54.67%-68.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650118545","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650118545?lang=zh_cn&edition=full","pubTime":"2026-07-10 17:00","pubTimestamp":1783674013,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","BK0239","300199","BK0070","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649662505","title":"翰宇药业最新公告：全资子公司化学原料药利拉鲁肽获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2649662505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649662505?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:11","pubTimestamp":1783336272,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司全资子公司翰宇药业(武汉)有限公司收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》，化学原料药利拉鲁肽(H)获批上市。利拉鲁肽是人胰高血糖素样肽-1(GLP-1)类似物，具有促进胰岛素分泌、保护胰岛β细胞等功能。公司是国内首家按化学合成途径获批利拉鲁肽的企业。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600030525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300199","BK0070","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648613396","title":"翰宇药业（300199）披露司美格鲁肽注射液（减重）上市申请获受理公告，7月3日股价上涨8.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648613396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648613396?lang=zh_cn&edition=full","pubTime":"2026-07-03 22:08","pubTimestamp":1783087691,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，翰宇药业报收于24.98元，较前一交易日上涨8.14%，最新总市值为220.63亿元。近日，翰宇药业披露《关于与三生蔓迪合作的司美格鲁肽注射液（减重）上市申请获得受理的公告》。公告显示，2026年7月2日，公司合作方浙江三生蔓迪药业有限公司提交的司美格鲁肽注射液（减重）上市申请已获国家药监局药品审评中心受理，共涉及5个规格，均为化药3类仿制品种。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300045409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","300199","BK0239","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648522653","title":"翰宇药业(300199.SZ)拟推2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2648522653","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648522653?lang=zh_cn&edition=full","pubTime":"2026-07-02 07:22","pubTimestamp":1782948146,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布2026年限制性股票激励计划(草案)，拟向激励对象授予不超过1950万股限制性股票，约占本激励计划草案公告时公司股本总额的2.21%。其中，首次授予1735万股，首次授予的激励对象不超过111人，授予价格为11.61元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","300199","BK0070","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189910245","title":"翰宇药业利拉鲁肽注射液获国家药监局批准用于治疗成人2型糖尿病","url":"https://stock-news.laohu8.com/highlight/detail?id=1189910245","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189910245?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:19","pubTimestamp":1782908361,"startTime":"0","endTime":"0","summary":"翰宇药业宣布，其研发的利拉鲁肽注射液已获得中国国家药品监督管理局的上市批准，适用于成人2型糖尿病的治疗。\n该药物的获批为国内2型糖尿病患者提供了一种新的治疗选择。利拉鲁肽作为一种GLP-1受体激动剂，在控制血糖方面已得到广泛认可。此次获批标志着翰宇药业在代谢疾病治疗领域取得了重要进展。\n公司表示，将积极推进该产品的商业化进程，以满足日益增长的市场需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0070","BK0077","BK0239","BK0028","BK0188","300199"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648548980","title":"翰宇药业：利拉鲁肽注射液获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2648548980","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648548980?lang=zh_cn&edition=full","pubTime":"2026-07-01 20:11","pubTimestamp":1782907881,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","300199","BK0028","BK0070","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647531713","title":"翰宇药业(300199.SZ)：替尔泊肽注射液降糖及减重2个ANDA获得美国FDA首仿受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2647531713","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647531713?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:40","pubTimestamp":1782812424,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 翰宇药业 发布公告，近日，公司向美国食品药品监督管理局申报的替尔泊肽注射液新药简略申请已获得FDA的受理审查通知。FDA已初步认定该ANDA 基本完整，予以受理审查。替尔泊肽是礼来公司研发的GLP-1R/GIPR双靶点激动剂，在全球减重及降糖药物市场中占据重要地位，全球尚无仿制药产品上市。根据礼来2025年财报数据，替尔泊肽2025年全球销售额合计约365.07亿美元，2025年全球销售额排名第一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","BK0188","BK0077","BK0239","BK4585","LABU","BK0028","300199","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146016058","title":"翰宇药业宣布美国FDA认定替尔泊肽注射液申请基本完整并接受审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1146016058","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146016058?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:16","pubTimestamp":1782810971,"startTime":"0","endTime":"0","summary":"翰宇药业表示，美国食品药品监督管理局已认定其替尔泊肽注射液的新药申请基本完整，并正式接受该申请进行审评。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300199","BK0077","BK0028","BK0239","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647348363","title":"股市必读：翰宇药业（300199）6月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2647348363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647348363?lang=zh_cn&edition=full","pubTime":"2026-06-29 01:03","pubTimestamp":1782666193,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，翰宇药业报收于19.77元，下跌10.1%，换手率6.2%，成交量46.23万手，成交额9.49亿元。董秘最新回复投资者： 董秘您好！公司将严格履行信息披露义务，相关重大进展将及时公告。公司公告汇总：控股股东曾少强于6月26日解除质押22,000,000股，占其所持股份比例34.84%，占公司总股本比例2.49%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900000327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0070","BK0188","300199","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646056357","title":"翰宇药业：公司今年上半年签订的1.8亿元及3.27亿元人民币的GLP-1原料药订单均属于框架性约定","url":"https://stock-news.laohu8.com/highlight/detail?id=2646056357","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646056357?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:53","pubTimestamp":1782478395,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业06月26日在投资者关系平台上答复投资者关心的问题。谢谢翰宇药业回复：尊敬的投资者，您好！公司今年上半年签订的1.8亿元及3.27亿元人民币的GLP-1原料药订单均属于框架性约定，具体采购金额以客户实际下达的订单为准，具体详见公司于2026年1月16日及5月20日披露的相关公告。公司将严格履行信息披露义务，相关重大进展将及时公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600042742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","CYB","MUCmain","BK0239","BK0070","MCNHmain","UCmain","BK0028","BK0188","BK0077","CNHmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645832927","title":"翰宇药业（300199）披露控股股东办理股票质押业务公告，6月23日股价下跌1.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645832927","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645832927?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:23","pubTimestamp":1782224598,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，翰宇药业报收于22.28元，较前一交易日下跌1.02%，最新总市值为196.79亿元。近日，翰宇药业披露《关于控股股东、实际控制人办理股票质押业务的公告》。公告显示，公司控股股东、实际控制人曾少强先生近期办理了部分股票质押业务，合计质押20,000,000股，占其所持股份比例31.68%，占公司总股本比例2.26%，质权人为深圳市中小担小额贷款有限公司，质押用途为融资担保。本次质押后，曾少强累计质押股份44,659,600股，占其所持股份70.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300199","BK0028","BK0070","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645395040","title":"翰宇药业(300199.SZ)子公司利那洛肽化学原料药获得上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645395040","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645395040?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:35","pubTimestamp":1782117338,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰宇药业(300199.SZ)发布公告，2026年6月21日，公司全资子公司翰宇药业(武汉)有限公司收到国家药品监督管理局下发的《化学原料药上市申请批准通知书》。利那洛肽是全球首个鸟苷酸环化酶-C(GC-C)激动剂，由美国Ironwood公司研发，于2012年8月经FDA批准上市，商品名为Linzess，适应症为成人慢性特发性便秘(CIC)和便秘型肠易激综合征(IBS-C)。该药于2019年1月15日经国家药品监督管理局(NMPA)批准在中国上市，商品名为令泽舒，由阿斯利康负责中国市场推广。截至目前，国内市场仍由原研药独占，尚无仿制药制剂获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0077","300199","BK0028","BK0188","BK0070","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641143825","title":"翰宇药业：流动性压力可控","url":"https://stock-news.laohu8.com/highlight/detail?id=2641143825","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641143825?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:53","pubTimestamp":1780663988,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业06月05日在投资者关系平台上答复投资者关心的问题。针对您的提问，公司回复如下：① 流动性压力：公司短期借款10.33亿元，但2025年经营性现金流净额达2.34亿元，已实现扭亏为盈，公司融资环境大为改善，偿债能力有保障，流动性风险可控。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500038867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","300199","BK0239","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641511390","title":"翰宇药业：公司相关项目已取得阶段性进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2641511390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641511390?lang=zh_cn&edition=full","pubTime":"2026-06-05 15:48","pubTimestamp":1780645684,"startTime":"0","endTime":"0","summary":"证券之星消息，翰宇药业(300199)06月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问翰宇董秘李总：就目前的市场情况，公司对仿药司美格鲁肽在国内上市后的市场怎么看待？国内市场公司司美格鲁肽的上市进度是否领先于同类产品？翰宇药业回复：尊敬的投资者，您好！公司已关注到司美格鲁肽化合物专利到期后国内仿制药市场的竞争趋势。公司相关项目已取得阶段性进展，相关工作正在推进中。目前国内有多个同类产品处于申报阶段，各家进度存在一定差异，公司最终获批时间尚存在不确定性，具体请以公司后续公告为准。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500022930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300199","BK0028","BK0077","BK0239","BK0188","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640244958","title":"翰宇药业最新公告：卡贝缩宫素原料药获欧盟DCP核准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640244958","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640244958?lang=zh_cn&edition=full","pubTime":"2026-06-01 18:10","pubTimestamp":1780308636,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，公司收到欧盟DCP核准文件，卡贝缩宫素原料药获欧盟分散审批程序核准，有助于拓宽海外市场，提升在欧盟及全球妇产科用药领域的竞争地位。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100029162.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","FSXEmain","BK0028","300199","BK0070","BK0188","BK0077","FESXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637819903","title":"翰宇药业（300199）披露2025年年度股东会决议公告，5月21日股价下跌3.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637819903","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637819903?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:47","pubTimestamp":1779356861,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，翰宇药业报收于22.75元，较前一交易日下跌3.19%，最新总市值为200.94亿元。该股当日开盘23.55元，最高24.0元，最低22.68元，成交额达10.71亿元，换手率为6.15%。公司于近日披露《2025年年度股东会决议公告》。公告显示，深圳翰宇药业股份有限公司于2026年5月20日召开2025年年度股东会，会议由董事会召集，采用现场与网络投票相结合方式举行。出席会议股东共363人，代表股份193,488,015股，占公司有表决权股份总数的21.9066%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100032976.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0070","BK0077","300199","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636858137","title":"翰宇药业最新公告：签订多肽原料药销售合作框架协议拟定销售金额不低于3.27亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636858137","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636858137?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:00","pubTimestamp":1779188409,"startTime":"0","endTime":"0","summary":"翰宇药业(300199.SZ)公告称，为拓宽海外业务布局、加快推进GLP-1原料药的商业化进程，公司与合作方于5月18日在深圳签署了多肽原料药销售合作框架协议，拟定销售金额不低于人民币3.27亿元，占公司最近一期经审计营业收入的33.84%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900035862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0077","BK0239","BK0028","300199"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784295690717,"stockEarnings":[{"period":"1week","weight":-0.0508},{"period":"1month","weight":0.0648},{"period":"3month","weight":0.1515},{"period":"6month","weight":0.1708},{"period":"1year","weight":0.2594},{"period":"ytd","weight":0.367}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0512},{"period":"3month","weight":-0.0417},{"period":"6month","weight":-0.0535},{"period":"1year","weight":0.1081},{"period":"ytd","weight":-0.0218}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳翰宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"98777人(较上一季度减少2.42%)","perCapita":"7543股","listingDate":"2011-04-07","address":"广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼","registeredCapital":"88324万元","survey":" 深圳翰宇药业股份有限公司的主营业务是多肽制剂、原料药、小核酸与CRDMO的研发、销售。公司的主要产品是多肽制剂、原料药、小核酸与CRDMO。","listedPrice":30.19},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"翰宇药业,300199,翰宇药业股票,翰宇药业股票老虎,翰宇药业股票老虎国际,翰宇药业行情,翰宇药业股票行情,翰宇药业股价,翰宇药业股市,翰宇药业股票价格,翰宇药业股票交易,翰宇药业股票购买,翰宇药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"翰宇药业(300199)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供翰宇药业(300199)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}